Lamina Propria Inflammation: Treatment Options

Treatment for lamina propria inflammation depends on what is driving it, but the options range from conventional anti-inflammatory drugs and biologics to newer small-molecule therapies, dietary strategies, and experimental approaches like cell therapy and targeted drug delivery. The lamina propria, the immune-cell-rich tissue layer sitting just beneath the surface lining of the gut, is ground zero for conditions like inflammatory bowel disease, eosinophilic disorders, and certain drug reactions. Because this tissue houses such a dense and varied collection of immune cells, the treatment landscape has expanded rapidly as researchers identify more of the specific pathways that keep inflammation going.

Why the Lamina Propria Is the Battleground

The lamina propria is packed with immune cells that normally patrol for harmful bacteria and other threats while tolerating the trillions of harmless microbes that live in the gut. This balancing act is delicate. When it breaks down, the immune system starts attacking the gut’s own tissue or overreacting to the resident microbial community. The lamina propria serves as a leukocyte-rich cornerstone of immune surveillance and barrier defense, housing a collaborative network of innate and adaptive immune cells that together maintain gut stability.¹

In inflammatory bowel disease, for example, the adaptive immune system loses its tolerance toward normal gut bacteria, and different arms of the immune response go into overdrive. Crohn’s disease tends to involve exaggerated Th1 and Th17 cell responses, while ulcerative colitis involves a distinct pattern with natural killer T cells and a characteristic cytokine mix including IL-13.² This distinction matters clinically because it means the same drug will not necessarily work equally well in both conditions, and treatment choices increasingly reflect which immune pathways are most active in a given patient.

Conventional Anti-Inflammatory and Immunosuppressive Drugs

The first-line approach for most cases of lamina propria inflammation in IBD remains aminosalicylates (5-ASA drugs like mesalamine), corticosteroids for flares, and immunomodulators such as azathioprine or methotrexate for maintenance. These are not targeted therapies in the modern sense. Aminosalicylates work locally in the gut lining to tamp down a broad set of inflammatory signals. Corticosteroids suppress the immune response more aggressively and across more pathways, which is why they work fast but come with significant side effects when used long term. Immunomodulators slow immune cell proliferation more broadly.

The overarching goal with any of these treatments, and with the newer options discussed below, is mucosal healing, meaning the visible inflammation on endoscopy resolves and, ideally, the microscopic inflammation in the lamina propria quiets down too.³ The push toward mucosal healing as a treatment target, rather than simply controlling symptoms, has reshaped how gastroenterologists evaluate every therapy in their toolkit.

Anti-TNF Biologics

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory molecules produced in the lamina propria during IBD flares. Anti-TNF drugs like infliximab and adalimumab were the first biologics approved for IBD and remain among the most widely used. Their mechanism goes beyond simply mopping up TNF-α in the tissue. Infliximab, for instance, causes a rapid and specific increase in programmed cell death among T lymphocytes in the gut mucosa, which helps explain why patients often improve quickly after infusion.⁴

The mechanism is more nuanced than just blocking a single molecule. Research has shown that anti-TNF antibodies work partly by disrupting a signaling loop between macrophages and T cells in the lamina propria. Macrophages displaying TNF on their surface interact with a receptor called TNFR2 on T cells, which activates survival signals that keep those T cells alive and inflammatory. When an anti-TNF antibody blocks that interaction, the T cells lose their survival advantage and undergo cell death.⁵ This indirect route to clearing inflammatory T cells may be as important as direct TNF neutralization.

Anti-Interleukin Biologics and Predicting Response

For patients who do not respond adequately to anti-TNF therapy, biologics targeting other cytokine pathways offer alternatives. Ustekinumab blocks both IL-12 and IL-23, two cytokines that drive the Th1 and Th17 immune responses prominent in Crohn’s disease. Not everyone responds equally, though, and emerging research suggests that the composition of immune cells in a patient’s lamina propria before treatment can predict outcomes. In one study, patients with Crohn’s disease who achieved remission on ustekinumab had a significantly higher baseline frequency of IL-23 receptor-expressing Th1 cells in their lamina propria compared to those who did not respond, roughly 21% versus 7%.⁶

This kind of finding points toward a future where treatment selection is guided by tissue-level biomarkers rather than trial and error. If your lamina propria immune profile shows heavy IL-23 receptor expression on T cells, ustekinumab may be a strong fit. If the inflammation is driven more by other pathways, a different biologic could be a better first choice. The field is not there yet in routine practice, but the direction is clear.

Anti-Integrin Therapy

A fundamentally different strategy involves stopping inflammatory cells from reaching the lamina propria in the first place. Vedolizumab does this by blocking an integrin molecule that gut-homing immune cells use to exit the bloodstream and enter intestinal tissue. Transcriptome analysis of patients on vedolizumab has shown impairment of signaling pathways associated with the adhesion, movement, and tissue infiltration of both granulocytes and other white blood cells.⁷ In practical terms, vedolizumab reduces the number of fresh immune cells arriving at the inflamed gut, giving the tissue a chance to calm down.

Because vedolizumab acts specifically on gut-directed immune trafficking rather than suppressing the immune system body-wide, it carries a lower risk of systemic infections compared to some other biologics. This gut selectivity makes it particularly attractive for patients concerned about infection risk or those who have experienced systemic side effects from broader immunosuppressants.

Small Molecule Therapies

The newest class of approved treatments includes oral small molecules that work through two distinct strategies. JAK inhibitors (tofacitinib, upadacitinib, filgotinib) block enzymes inside immune cells that relay signals from inflammatory cytokines. By interrupting this relay, they prevent the activation of downstream proteins that drive gene expression in inflammatory pathways.⁸ A case study of JAK inhibitor treatment demonstrated a marked decrease in activated signaling proteins within both epithelial cells and lamina propria lymphocytes, providing direct histological evidence that these drugs reach and affect the tissue where inflammation lives.⁹

S1P receptor modulators (ozanimod, etrasimod) take the anti-integrin concept a step further. They work by trapping lymphocytes in the lymph nodes so they cannot circulate to the gut at all. By binding to receptors on the surface of lymphocytes, these drugs prevent the cells from exiting lymphoid tissue and migrating toward inflamed intestinal mucosa.⁸ Both classes of small molecules have the practical advantage of being pills rather than infusions or injections, which matters for long-term adherence.

Dietary and Nutritional Approaches

Not all treatment for lamina propria inflammation requires drugs. Exclusive enteral nutrition, a liquid formula diet that replaces all regular food for a period of weeks, is an established therapy for Crohn’s disease, particularly in children. It works through several routes: reshaping the gut microbiome by pushing out potentially harmful bacteria from the mucus layer, increasing the abundance of protective microbial species, and modulating metabolic pathways in the intestinal lining and immune cells.¹⁰

Animal research has helped clarify the immunological mechanism. In a mouse model, enteral nutrition enriched with prebiotics protected against colitis by expanding anti-inflammatory T cell populations in the lamina propria, including regulatory T cells that produce the calming cytokine IL-10 and cells that produce IL-22, which supports barrier repair.¹¹ The idea that diet can shift the immune balance within the lamina propria itself, not just improve symptoms, is a significant development and one reason nutritional therapy is taken seriously alongside pharmacological options.

Microbiome-Based Treatments

Fecal microbiota transplant has attracted considerable attention as a way to reset a disrupted gut microbial community, and several clinical trials have shown benefit in ulcerative colitis. The approach is still evolving. One line of preclinical work has explored using extracellular vesicles, tiny packages of signaling molecules shed by gut bacteria, as a more refined alternative to whole-stool transplant. In mouse models of ulcerative colitis, vesicles from microbiota that had been pre-conditioned with a nanomedicine outperformed standard fecal transplant in reducing colonic inflammation, restoring barrier function, and rebalancing the microbial community.¹² This is still laboratory-stage work, but it illustrates the direction: toward more controlled, defined microbial therapies rather than transferring an entire unknown ecosystem.

Cell Therapy and Regenerative Medicine

Mesenchymal stem cells, which can be harvested from bone marrow, fat tissue, or umbilical cord, have anti-inflammatory and tissue-repair properties that make them candidates for treating stubborn lamina propria inflammation. In perianal Crohn’s disease, local injection of these cells is already approved in some regions for treating fistulas. The systemic effects are also being studied. In an animal model of colitis, mesenchymal stem cell therapy not only reduced acute inflammation but appeared to train the innate immune system in a lasting way. When animals were re-exposed to a colitis trigger, those that had previously received stem cells showed a higher ratio of anti-inflammatory to pro-inflammatory macrophages in the lamina propria, along with increased expression of markers associated with tissue repair.¹³

The concept of an immune memory effect from cell therapy is intriguing. Rather than just suppressing inflammation temporarily, the treatment may reprogram the local immune environment to handle future insults more gracefully. Whether this finding translates to sustained benefits in human IBD patients is still being tested, but it represents a different philosophy of treatment: reshaping immune behavior rather than continuously blocking it.

Treating Eosinophilic Lamina Propria Inflammation

Not all lamina propria inflammation looks the same under the microscope. In eosinophilic esophagitis, the infiltrating cells are predominantly eosinophils rather than the T cells and macrophages that dominate IBD. This distinction has driven development of targeted therapies like dupilumab, a biologic that blocks IL-4 and IL-13 signaling. In the LIBERTY EoE TREET trial, dupilumab improved most histological component scores compared to placebo by week 24, and patients who continued on the drug saw further improvement at week 52. Patients who switched from placebo to dupilumab at week 24 caught up to those who had been on active treatment from the start.¹⁴

The success of dupilumab in eosinophilic esophagitis underscores a broader principle: effective treatment of lamina propria inflammation requires correctly identifying the type of inflammation present. A therapy designed for T-cell-driven Crohn’s disease would not be expected to help an eosinophil-predominant condition, and vice versa. Histological evaluation of the lamina propria, not just symptom assessment, is what guides this distinction.

When Drugs Cause the Inflammation

Sometimes lamina propria inflammation is not driven by an autoimmune or allergic process but by a medication. An ever-growing list of drugs, including newer immunotherapeutic agents and targeted cancer therapies, can cause gastrointestinal inflammation of varying severity. The challenge is that a single drug can produce multiple different patterns of injury in the gut, including patterns that closely mimic IBD.¹⁵ Immune checkpoint inhibitors used in cancer treatment are a common culprit; they release the brakes on the immune system to fight tumors, but the gut often becomes collateral damage.

The treatment in these cases can be quite different from IBD management. Stopping the offending medication may be enough to resolve the inflammation entirely, making recognition of drug-induced mucosal injury critically important. When that is not possible, such as when the medication is essential for cancer treatment, corticosteroids or infliximab are sometimes used to manage the gut inflammation while continuing the cancer therapy. Getting the diagnosis right prevents patients from being started on long-term IBD medications they do not need.

Monitoring Response With Biomarkers

Tracking whether treatment is actually reducing lamina propria inflammation historically required repeat endoscopy and biopsy, which is invasive and impractical for frequent monitoring. Fecal calprotectin, a protein released by neutrophils in inflamed gut tissue, has become the most widely used non-invasive marker. A meta-analysis found that fecal calprotectin can identify histological remission in ulcerative colitis with a pooled sensitivity of about 76% and specificity of about 71%.¹⁶ Those numbers are reasonable but far from perfect, meaning some patients with persistent histological inflammation will have a reassuringly low calprotectin result and vice versa.

Low calprotectin levels correlate well with both histological remission and the absence of basal plasmacytosis, which is an important microscopic marker of deep mucosal healing in both ulcerative colitis and colonic Crohn’s disease.¹⁷ In practice, most clinicians use calprotectin as a screening tool: if it is low, the lamina propria is likely quiet and endoscopy can be deferred. If it rises, further investigation is warranted. The cutoff values used in studies range from 50 to over 170 micrograms per gram, and there is no universal agreement on the best threshold, which is worth keeping in mind if you are tracking your own results over time.

Endoscopic and Surgical Options for Complications

When chronic lamina propria inflammation leads to structural damage, particularly the fibrotic strictures common in Crohn’s disease, treatment shifts from managing immune activity to physically opening up narrowed segments of bowel. Endoscopic balloon dilation, endoscopic stricturotomy, and self-expanding metal stents are the main tools for fibrotic or mixed strictures and can delay or replace surgery in properly selected patients.¹⁸ These interventions do not treat the underlying inflammation but address its consequences, and they are increasingly seen as a bridge between medical therapy and surgery rather than a last resort.

Surgery remains necessary when medical and endoscopic options are exhausted, when complications like abscesses or fistulas are not responsive to biologic therapy, or when dysplasia or cancer develops in chronically inflamed tissue. The decision to operate is rarely about a single failed drug. It reflects the accumulated damage from inflammation that was not adequately controlled, which is why the emphasis on achieving deep mucosal and histological healing has become so prominent in treatment guidelines.

Emerging Drug Delivery and the Neuro-Immune Frontier

One of the ongoing challenges with treating lamina propria inflammation is getting the right amount of drug to the right spot. Systemic immunosuppression works but comes with body-wide side effects. Nanoparticle-based delivery systems are being developed to concentrate drugs at the site of intestinal inflammation, extend how long the drug stays in contact with diseased tissue, and minimize systemic exposure.¹⁹ None of these systems have reached routine clinical use yet, but the concept is being applied to corticosteroids, biologics, and small molecules alike.

An entirely different research frontier involves the neuro-immune axis, the communication network between the gut’s own nervous system and its resident immune cells. Neurons in the gut wall signal directly to immune cells in the lamina propria and vice versa, and the microbiome participates in this crosstalk as well.²⁰ Vagus nerve stimulation, which has been explored for rheumatoid arthritis and is being tested in IBD, may influence gut inflammation by leveraging these neural-immune connections. The science here is still early, but it raises the possibility that future treatments for lamina propria inflammation could include approaches that look nothing like traditional drugs.

Targeting Specific Immune Signals Within the Lamina Propria

Beyond the approved biologics, researchers are exploring more precise ways to intervene in the inflammatory loops that sustain lamina propria damage. One example involves TREM-1, a receptor found on myeloid cells like macrophages and neutrophils in inflamed tissue. In IBD patients, inflamed lamina propria tissue contains elevated levels of a molecule called PGLYRP-1, produced mainly by neutrophils, that activates TREM-1 and drives the release of pro-inflammatory cytokines. An antibody blocking TREM-1 reduced the secretion of several of these cytokines by lamina propria cells taken from IBD patients.²¹

Similarly, single-cell analysis of the lamina propria in ulcerative colitis has identified genes linked to macrophage polarization, the process by which macrophages shift between pro-inflammatory and tissue-repair states. One such gene, ANXA5, was found to be upregulated in intestinal macrophages during colitis and negatively correlated with the anti-inflammatory macrophage subtype, suggesting it may help tip the balance toward ongoing inflammation.²² These findings are still in the discovery phase, but they illustrate how treatment options could become increasingly tailored to the specific immune imbalance in a given patient’s gut tissue rather than relying on broad suppression of the whole system.